[Retracted] Exosomal miRNA Expression Profiling and the Roles of Exosomal miR-4741, miR-32, miR-3149, and miR-6727 on Gastric Cancer Progression

Figure 5

Exosomal miR-4741, miR-32, miR-3149, and miR-6727 as promising markers for diagnosing gastric cancer. (a) Comparisons of age distribution among healthy, early gastric cancer and middle-advanced gastric cancer. (b) Differences in serum ProGRP levels in early and middle-advanced gastric cancer. (c) Comparisons of serum CEA levels among healthy, early gastric cancer and middle-advanced gastric cancer. (d) Differences in serum CA199 levels among healthy, early gastric cancer and middle-advanced gastric cancer. (e) Comparisons of the expression of exosomal miR-3149, miR-32, miR-4741, and miR-6727 in healthy subjects and gastric cancer patients. (f–i) Comparisons of the expressions of exosomal (f) miR-4741, (g) miR-32, (h) miR-3149 as well as (i) miR-6727 among healthy, early gastric cancer and middle-advanced gastric cancer. (j–m) ROC curves of evaluating the efficacy of exosomal (j) miR-4741, (k) miR-32, (l) miR-3149, and (m) miR-6727 expression for diagnosing gastric cancer. (n–q) External validation of exosomal (n) miR-4741, (o) miR-32, (p) miR-3149, and (q) miR-6727 expression in gastric cancer patients and healthy subjects in the GSE86822 dataset. Ns: not significant; ; ; ; .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)

(o)

(p)

(q)